AstraZeneca has received EU approval for its combination therapy of Imfinzi (durvalumab) and Lynparza (olaparib) to treat specific patients with advanced or recurrent endometrial cancer. The approval is based on data from the DUO-E study showing significant reductions in disease progression or death for both mismatch repair proficient and deficient patients.